Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 1

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 4(3)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03785652Phase 1Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Role: collaborator

NCT01282619Phase 2Unknown

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

Role: lead

NCT00606515Phase 4Completed

Pharmacokinetics Study of Liposomal Paclitaxel in Humans

Role: lead

NCT00642239Phase 4Unknown

A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma

Role: lead

NCT00622986Phase 4Unknown

China Cimicifuga Trial of Climacteric Complaint Control

Role: lead

All 5 trials loaded